×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
JAZZ – jazz pharmaceuticals plc - ordinary shares (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
JAZZ
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
12/3
04:31 pm
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
12/2
04:26 pm
jazz
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium [Yahoo! Fina
Low
Report
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium [Yahoo! Fina
12/2
04:05 pm
jazz
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
Low
Report
Jazz Pharmaceuticals to Present Pivotal Phase 3 Results of Ziihera® (zanidatamab-hrii) Combinations in First-Line HER2-Positive Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma at the 2026 ASCO Gastrointestinal Cancers Symposium
11/27
07:07 pm
jazz
A Look at Jazz Pharmaceuticals's Valuation After Breakthrough Phase 3 Ziihera Trial Results [Yahoo! Finance]
Low
Report
A Look at Jazz Pharmaceuticals's Valuation After Breakthrough Phase 3 Ziihera Trial Results [Yahoo! Finance]
11/27
02:49 pm
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) had its "sell (d+)" rating reaffirmed by analysts at Weiss Ratings.
11/25
07:31 am
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by analysts at UBS Group AG from a "strong-buy" rating to a "hold" rating.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by analysts at UBS Group AG from a "strong-buy" rating to a "hold" rating.
11/24
07:19 am
jazz
Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.
Low
Report
Jazz Pharmaceuticals (NASDAQ:JAZZ) was downgraded by analysts at UBS Group AG from a "buy" rating to a "neutral" rating.
11/18
04:15 pm
jazz
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Low
Report
Jazz Pharmaceuticals to Participate in Citi's 2025 Global Healthcare Conference
Date
Time
Symbol
Company Name
Action
%Chg
11/5/2025
04:05 pm
jazz
jazz pharmaceuticals plc - ordinary shares
BEAT
Report
-2.3%
jazz pharmaceuticals plc - ordinary shares
8/5/2025
04:05 pm
jazz
jazz pharmaceuticals plc - ordinary shares
MISS
Report
-6.4%
jazz pharmaceuticals plc - ordinary shares
5/6/2025
04:08 pm
jazz
jazz pharmaceuticals plc - ordinary shares
MISS
Report
-3.4%
jazz pharmaceuticals plc - ordinary shares
2/25/2025
04:05 pm
jazz
jazz pharmaceuticals plc - ordinary shares
BEAT
Report
3.2%
jazz pharmaceuticals plc - ordinary shares
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
12/4
05:48 pm
jazz
Form 4 Jazz Pharmaceuticals For: Dec 02 Filed by: O'Keefe Kenneth W
Low
Report
Form 4 Jazz Pharmaceuticals For: Dec 02 Filed by: O'Keefe Kenneth W
12/1
08:55 pm
jazz
Form 144 Jazz Pharmaceuticals Filed by: O'Keefe Kenneth W
Medium
Report
Form 144 Jazz Pharmaceuticals Filed by: O'Keefe Kenneth W
12/1
06:14 pm
jazz
Form 4 Jazz Pharmaceuticals For: Nov 26 Filed by: COZADD BRUCE C
Medium
Report
Form 4 Jazz Pharmaceuticals For: Nov 26 Filed by: COZADD BRUCE C
11/26
05:37 pm
jazz
Form 144 Jazz Pharmaceuticals Filed by: COZADD BRUCE C
Low
Report
Form 144 Jazz Pharmaceuticals Filed by: COZADD BRUCE C
11/24
05:48 pm
jazz
Form 4 Jazz Pharmaceuticals For: Nov 20 Filed by: McSharry Heather Ann
Low
Report
Form 4 Jazz Pharmaceuticals For: Nov 20 Filed by: McSharry Heather Ann
11/21
04:35 pm
jazz
Form 4 Jazz Pharmaceuticals For: Nov 19 Filed by: Henderson Mary Elizabeth
Low
Report
Form 4 Jazz Pharmaceuticals For: Nov 19 Filed by: Henderson Mary Elizabeth
11/20
08:03 pm
jazz
Form 4 Jazz Pharmaceuticals For: Nov 18 Filed by: COZADD BRUCE C
Low
Report
Form 4 Jazz Pharmaceuticals For: Nov 18 Filed by: COZADD BRUCE C
11/20
06:14 pm
jazz
Form 4 Jazz Pharmaceuticals For: Nov 18 Filed by: Carr Patricia
Low
Report
Form 4 Jazz Pharmaceuticals For: Nov 18 Filed by: Carr Patricia
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/7
Q1/2019 3/31/2019 EPS 3.670 ZacksConsensus 2.830 ActVsEst 0.840 - Beat
9.3%
4/6 Jefferies sees 51% upside in Jazz Pharma in premarket analyst action [Seeking Alpha] 7.1%
9/10 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. 5.0%
11/14 Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences 3.7%
11/7 Form 3 Jazz Pharmaceuticals For: Oct 31 Filed by: Larkin Finbar 3.3%
1/14 Form 8-K Jazz Pharmaceuticals For: Jan 13 3.0%
4/24 Form 10-K/A Jazz Pharmaceuticals For: Dec 31 2.8%
12/19 PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S. 2.6%
11/22 Edited Transcript of JAZZ earnings conference call or presentation 5-Nov-19 9:30pm GMT [Yahoo! Finance News] 2.6%
4/28 Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy? [The Motley Fool] 2.5%
4/6 Jefferies sees 51% upside in Jazz Pharma in premarket analyst action [Seeking Alpha] 7.1%
9/10 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was downgraded by analysts at ValuEngine from a "sell" rating to a "strong sell" rating. 5.0%
11/14 Jazz Pharmaceuticals Announces Participation at Upcoming Investor Conferences 3.7%
11/7 Form 3 Jazz Pharmaceuticals For: Oct 31 Filed by: Larkin Finbar 3.3%
1/14 Form 8-K Jazz Pharmaceuticals For: Jan 13 3.0%
4/24 Form 10-K/A Jazz Pharmaceuticals For: Dec 31 2.8%
12/19 PharmaMar and Jazz Pharmaceuticals Sign Exclusive License Agreement for Lurbinectedin in the U.S. 2.6%
11/22 Edited Transcript of JAZZ earnings conference call or presentation 5-Nov-19 9:30pm GMT [Yahoo! Finance News] 2.6%
4/28 Can This Small-Cap Biotech Win a $1 Billion Market Opportunity for Narcolepsy? [The Motley Fool] 2.5%
TOP News Decliners
3/13
Form 4 Jazz Pharmaceuticals For: Mar 12 Filed by: MILLER MICHAEL PATRICK
-11.3%
2/25 Q4/2019 12/31/2019 EPS 4.420 ZacksConsensus 3.610 ActVsEst 0.810 - Beat -8.4%
3/3 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -7.8%
6/17 Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol) -7.1%
10/7 Form 8-K Jazz Pharmaceuticals For: Oct 03 -5.6%
8/6 Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results -4.8%
11/5 Jazz Pharmaceuticals EPS beats by $0.51, beats on revenue [Seeking Alpha] -4.3%
3/31 Jazz Pharmaceuticals Provides COVID-19 Business Update -4.1%
3/5 Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Carr Patricia -3.8%
4/29 Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease -3.6%
2/25 Q4/2019 12/31/2019 EPS 4.420 ZacksConsensus 3.610 ActVsEst 0.810 - Beat -8.4%
3/3 Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -7.8%
6/17 Jazz Pharmaceuticals Receives Schedule IV Designation from DEA for Sunosi™ (solriamfetol) -7.1%
10/7 Form 8-K Jazz Pharmaceuticals For: Oct 03 -5.6%
8/6 Jazz Pharmaceuticals Announces Second Quarter 2019 Financial Results -4.8%
11/5 Jazz Pharmaceuticals EPS beats by $0.51, beats on revenue [Seeking Alpha] -4.3%
3/31 Jazz Pharmaceuticals Provides COVID-19 Business Update -4.1%
3/5 Form 4 Jazz Pharmaceuticals For: Mar 03 Filed by: Carr Patricia -3.8%
4/29 Jazz Pharmaceuticals Stops Enrollment in Phase 3 Study Evaluating Defibrotide for the Prevention of Veno-Occlusive Disease -3.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: